Document is current
Any future updates will be listed below
-
Authors
Chen, Briana K.
Hunsberger, Holly C.
Whye, Alicia
Matthews, Louise C.
Yook, Alyson
Willner, Moshe J.
Logan, Ryan W.
Johns, Stefanie
Weisblum, Eric
Denny, Christine A.
-
Funding
Funding for this research was provided by:
Silo Pharma
- License Information
-
More Information
Article History
Received: 29 April 2025
Accepted: 30 June 2025
First Online: 15 July 2025
Declarations
:
: All procedures were conducted in accordance with the National Institutes of Health (NIH) regulations and by the Institutional Animal Care and Use Committees (IACUCs) of Columbia University Irving Medical Center (CUIMC) and the Research Foundation for Mental Hygiene, Inc. (RFMH) at the New York State Psychiatric Institute (NYSPI).
: BKC, HCH, and CAD are named on provisional patent applications for the prophylactic use of (R,S)-ketamine, 5-HT4R agonists, and other compounds against stress-related psychiatric disorders and Alzheimer’s disease. SJ is employed by Silo Pharma, and EW is founder and Chief Executive Officer of Silo Pharma. AW, LCM, AY, MJW, and RL have no conflicts of interest to disclose.
